ViroMissile

CompanyUnited States

ViroMissile develops one asset, in phase 1 (IDOV-2 in advanced solid tumor). Mostly other; based in the United States.

1
Asset
Furthest stage
Phase 1
0
Trials
0
Signals

Pipeline

1
  • IDOV-2

    Intravenously deliverable oncolytic virus for cancer immunotherapy.

    Phase 1, Other, advanced solid tumor, solid tumor

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Similar companies6

Intelligence